CA2012194A1 - Compose pharmaceutique solide contenant de la nifedipine - Google Patents

Compose pharmaceutique solide contenant de la nifedipine

Info

Publication number
CA2012194A1
CA2012194A1 CA2012194A CA2012194A CA2012194A1 CA 2012194 A1 CA2012194 A1 CA 2012194A1 CA 2012194 A CA2012194 A CA 2012194A CA 2012194 A CA2012194 A CA 2012194A CA 2012194 A1 CA2012194 A1 CA 2012194A1
Authority
CA
Canada
Prior art keywords
weight
nifedipine
tablets
active ingredient
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2012194A
Other languages
English (en)
Other versions
CA2012194C (fr
Inventor
Sandor Erdos
Jozsef Kenderfi
Erzsebet Barczay
Aranka Hegedus
Maria Krisztian
Attila Mandi
Eva Tajthy
Peter Tompe
Margit Csorgo
Marton Fekete
Frigyes Gorgenyi
Zoltan Torma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10953380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2012194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2012194A1 publication Critical patent/CA2012194A1/fr
Application granted granted Critical
Publication of CA2012194C publication Critical patent/CA2012194C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002012194A 1989-03-14 1990-03-14 Compose pharmaceutique solide contenant de la nifedipine Expired - Fee Related CA2012194C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1215/89 1989-03-14
HU891215A HU203041B (en) 1989-03-14 1989-03-14 Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin

Publications (2)

Publication Number Publication Date
CA2012194A1 true CA2012194A1 (fr) 1990-09-14
CA2012194C CA2012194C (fr) 1995-10-31

Family

ID=10953380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002012194A Expired - Fee Related CA2012194C (fr) 1989-03-14 1990-03-14 Compose pharmaceutique solide contenant de la nifedipine

Country Status (20)

Country Link
US (1) US5108757A (fr)
EP (1) EP0387782B2 (fr)
JP (1) JPH02279626A (fr)
AT (1) AT402889B (fr)
BG (1) BG91467A (fr)
CA (1) CA2012194C (fr)
CH (1) CH680416A5 (fr)
CY (1) CY1762A (fr)
CZ (1) CZ277897B6 (fr)
DD (1) DD294415A5 (fr)
DE (1) DE59008160D1 (fr)
FR (1) FR2644343B1 (fr)
GB (1) GB2229095B (fr)
GR (1) GR1002295B (fr)
HK (1) HK218696A (fr)
HU (2) HU203041B (fr)
IT (1) IT1240605B (fr)
RU (1) RU1837874C (fr)
UA (1) UA19285A (fr)
YU (1) YU47691B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
WO1994005262A1 (fr) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Composition sous forme de matrice a liberation prolongee
JP3140465B2 (ja) * 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
JP3148256B2 (ja) * 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
EP1202716A1 (fr) * 1999-08-17 2002-05-08 Novartis Consumer Health S.A. Forme galenique a dissolution rapide et procede de fabrication associe
ATE391495T1 (de) * 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
MXPA02005562A (es) * 1999-12-06 2004-09-10 Penwest Pharmaceuticals Co Superdesintegrante farmaceutico.
CA2311734C (fr) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Forme pharmaceutique orale a dissolution ultra-rapide
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
WO2003080057A1 (fr) * 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Comprime-noyau de taille reduite contenant de la nifedipine
DE10315640A1 (de) * 2003-04-04 2004-10-14 Ignatov, Konstantin Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
IE20100799A1 (en) * 2010-12-22 2012-08-01 Eurand Pharmaceuticals Ltd Pharmaceutical composites of poorly water soluble drugs and polymers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001247A1 (fr) * 1977-09-14 1979-04-04 Kanebo, Ltd. Composition pharmaceutique contenant de la nifédipine et procédé pour sa préparation.
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (fr) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
EP0078430B2 (fr) * 1981-10-29 1993-02-10 Bayer Ag Procédé de fabrication de préparations pharmaceutiques solides à libération rapide de dihydropyridines
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
EP0207638B1 (fr) * 1985-06-04 1990-12-19 Teijin Limited Préparation pharmaceutique à liberation prolongé
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3639073A1 (de) * 1986-11-14 1988-05-26 Klinge Co Chem Pharm Fab Feste arzneizubereitungen und verfahren zu ihrer herstellung
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix

Also Published As

Publication number Publication date
JPH02279626A (ja) 1990-11-15
BG91467A (bg) 1993-12-24
CZ277897B6 (en) 1993-06-16
EP0387782A3 (fr) 1991-03-13
GR900100179A (el) 1991-07-31
AT402889B (de) 1997-09-25
ATA60690A (de) 1997-02-15
IT9019677A0 (it) 1990-03-14
RU1837874C (ru) 1993-08-30
FR2644343A1 (fr) 1990-09-21
GB2229095B (en) 1993-02-10
CH680416A5 (fr) 1992-08-31
HU211507A9 (en) 1995-11-28
DD294415A5 (de) 1991-10-02
FR2644343B1 (fr) 1994-10-21
HK218696A (en) 1997-01-03
GB9005730D0 (en) 1990-05-09
DE59008160D1 (de) 1995-02-16
YU47691B (sh) 1996-01-08
UA19285A (uk) 1997-12-25
YU45890A (en) 1992-05-28
CY1762A (en) 1994-07-15
EP0387782B1 (fr) 1995-01-04
HU203041B (en) 1991-05-28
EP0387782B2 (fr) 1996-11-06
EP0387782A2 (fr) 1990-09-19
IT1240605B (it) 1993-12-17
GR1002295B (el) 1996-05-03
GB2229095A (en) 1990-09-19
US5108757A (en) 1992-04-28
CA2012194C (fr) 1995-10-31
HUT54046A (en) 1991-01-28
IT9019677A1 (it) 1991-09-14

Similar Documents

Publication Publication Date Title
CA2012194A1 (fr) Compose pharmaceutique solide contenant de la nifedipine
US5264446A (en) Solid medicament formulations containing nifedipine, and processes for their preparation
RU2227019C2 (ru) Твердый фармацевтический препарат, содержащий ингибитор hmg-coa-редуктазы
CA1255227A (fr) Methode de production d'une preparation stable de nicorandil
JPS5914446B2 (ja) ニフエジピン含有固形製剤及びその製造方法
CA2245708A1 (fr) Formulations solides contenant du trehalose
SE451668B (sv) Farmaceutisk komposition innehallande amoxycillintrihydrat, kaliumklavulanat och ett torkmedel i en sluten behallare
HUT63407A (en) Process for producing substituted indole, indene, piranoindole and tetrahydrocarbazole alkanoic acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
BG65011B1 (bg) Усъвършенствани бързоразпадащи се таблетки
IE55140B1 (en) Stable pharmaceutical tablet
HU900118D0 (en) Process for preparation of new cyclic amine-derivatives and for manufacturing of pharmaceutical compositions containing these compounds as active ingredient
HU892559D0 (en) Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient
TW223592B (fr)
JPH0576921B2 (fr)
KR910014120A (ko) 피모벤단의 경구용 약제학적 제제
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
CA1285486C (fr) Methode de production d'une preparation stable de nicorandil
CN1131910A (zh) 含碱金属和/或金属敏感性药用活性物质的泡腾体系及其制造方法
EP0168360A3 (en) Process for preparing etofibrate or similar compounds containing sustained release microgranules and products thus obtained
KR0177493B1 (ko) 단사정계 결정구조를 갖고 감열, 감광 및 감습성이 있는 활성성분을 함유하는 정제의 제조방법
KR920006908B1 (ko) 디히드로피리딘을 함유하는 고상 약제의 제조 방법
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
JPS5883617A (ja) ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物及びその製造方法
EP0773783A1 (fr) Preparation de comprimes a base d'acide fusidique
WO1999058527A3 (fr) Derives de benzofuranne, composition pharmaceutique renfermant ces derives et procede de preparation du principe actif

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed